Having observed that inhibition of Sirt1 played a role in the “fine-tuning” of circadian gene oscillation and in the case of CML led to a complete recovery of BMAL1 oscillation, we next wanted to see whether treatment of patient samples with EX527 altered the relative expression of the circadian genes and how soon after treatment were these changes noticeable. The gene discussed is BMAL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.